Cordis will have access to Medinol's latest generation stainless steel and cobalt chromium bare metal stents. Medinol's advanced stents balance deliverability, conformability and scaffolding qualities to provide ease of use, safety and long-term results.
Cordis Corporation and Medinol will work together to obtain necessary approvals to market the products globally from U.S. and other regulatory authorities.
"We are pleased to provide physicians with an increasing array of products for their interventional procedures," said Rick Anderson, Company Group Chairman, Cordis Corporation.
"The partnership of Medinol and Cordis, the global leader in interventional cardiology, is ideal for physicians and the patients they treat," said Kobi Richter, Ph.D., Chairman and Chief Technology Officer, Medinol. "With our broad product portfolio, physicians can choose the stent that best meets the needs of each individual patient. We are excited about the opportunity to present our current and future technologies to physicians through our partnership with Cordis."
Cordis Corporation estimates that the first applications for approval of the Medinol bare metal stent products will be filed outside the United States in the second half of 2007 and in the United States in the first half of 2008.
Cordis Corporation, an Amrican medical device corporation and a pioneer in innovative devices and products for interventional vascular medicine and electrophysiology, announced that it has signed a definitive agreement whereby it will become the exclusive global distributor of a family of bare metal stents for coronary applications developed by the Israeli medical company Medinol.